MX2016016063A - Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. - Google Patents

Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.

Info

Publication number
MX2016016063A
MX2016016063A MX2016016063A MX2016016063A MX2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A
Authority
MX
Mexico
Prior art keywords
mic
compounds
fusion proteins
relates
terminus
Prior art date
Application number
MX2016016063A
Other languages
English (en)
Inventor
Thøgersen Henning
Vilbour Andersen Kim
HELGSTRAND Charlotte
Paolo Bastner SANDRINI Michael
Beck Jørgensen Sebastian
Sass-Ørum Kristian
Hastrup Sven
Christian Shaw Allan
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2016016063A publication Critical patent/MX2016016063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a proteínas de fusión de MIC-1. De manera más específica, se refiere a compuestos que comprenden proteínas de fusión que comprenden una proteína MIC-1 o un análogo de la misma en el C-terminal-terminal de la proteína de fusión y una variante funcional de la albúmina de suero humano en el N-terminal de la proteína de fusión conectada a través de un enlazador peptídico. Los compuestos de la invención tienen actividad de MIC-1. La invención también se refiere a composiciones farmacéuticas que comprenden esos compuestos y excipientes farmacéuticamente aceptables, así como el uso médico de los compuestos.
MX2016016063A 2014-06-24 2015-06-17 Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. MX2016016063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173664 2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en) 2014-06-24 2015-06-17 Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2016016063A true MX2016016063A (es) 2017-03-10

Family

ID=51032955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016063A MX2016016063A (es) 2014-06-24 2015-06-17 Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.

Country Status (15)

Country Link
US (2) US9272019B2 (es)
EP (1) EP3160496B1 (es)
JP (1) JP6696915B2 (es)
KR (1) KR20170020383A (es)
CN (1) CN106459222A (es)
AR (1) AR100945A1 (es)
AU (1) AU2015279525A1 (es)
BR (1) BR112016029848A2 (es)
CA (1) CA2952293A1 (es)
IL (1) IL249327A0 (es)
MX (1) MX2016016063A (es)
RU (1) RU2017101436A (es)
TW (1) TW201613958A (es)
WO (1) WO2015197446A1 (es)
ZA (1) ZA201608214B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
NZ754961A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
BR112018072034A2 (pt) * 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
EP3551214B1 (en) 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700553D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
JP2020517657A (ja) 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
MX2020010659A (es) 2018-04-09 2020-10-28 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15.
KR20210044244A (ko) 2018-08-10 2021-04-22 노파르티스 아게 Gfral 세포외 도메인 및 사용 방법
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2022089435A1 (en) * 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
CN112694520B (zh) * 2020-12-02 2023-01-17 图凌(杭州)生物医药有限公司 一种人工多肽hm、其抗体及在病理检测中的应用
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
KR20090006221A (ko) * 2004-07-26 2009-01-14 아스테리온 리미티드 연결체들
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US9714276B2 (en) * 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
US9550819B2 (en) * 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
NZ754961A (en) 2013-07-31 2022-04-29 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs

Also Published As

Publication number Publication date
TW201613958A (en) 2016-04-16
BR112016029848A2 (pt) 2017-10-24
WO2015197446A1 (en) 2015-12-30
KR20170020383A (ko) 2017-02-22
AR100945A1 (es) 2016-11-09
CN106459222A (zh) 2017-02-22
RU2017101436A3 (es) 2019-02-13
EP3160496B1 (en) 2021-03-03
US20160015784A1 (en) 2016-01-21
RU2017101436A (ru) 2018-07-24
US20160129083A1 (en) 2016-05-12
CA2952293A1 (en) 2015-12-30
JP2017528419A (ja) 2017-09-28
EP3160496A1 (en) 2017-05-03
US9272019B2 (en) 2016-03-01
US9956264B2 (en) 2018-05-01
AU2015279525A1 (en) 2016-12-15
JP6696915B2 (ja) 2020-05-20
ZA201608214B (en) 2018-11-28
IL249327A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
TW201613958A (en) MIC-1 fusion proteins and uses thereof
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2016010951A (es) Proteinas de fc multimericas.
MY187047A (en) Selective pyy compounds and uses thereof
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
MX2016010953A (es) Proteinas de fc multimericas.
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
MX371033B (es) Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2013007872A (es) Proteina de fusion anticancer.
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2020007628A (es) Composiciones y metodos de uso.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
PH12017500742A1 (en) Statherin peptides
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung